Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485504 | 0.88 | ADORA3 (0.38) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3484982 | 0.86 | ADORA2A (0.37) | ADORA2AADORA3ADORA1CCNA2CDK2 | |
| SCHEMBL13777743 | 0.86 | ADORA2A (0.37) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3478717 | 0.82 | ADORA2A (0.41) | ADORA2AADORA3ADORA1CDK2ADORA2B | |
| SCHEMBL13645791 | 0.81 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393443 | 0.81 | ADORA2A (0.42) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393607 | 0.80 | ADORA2A (0.42) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393327 | 0.80 | ADORA2A (0.42) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13777730 | 0.80 | ADORA2A (0.42) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13777773 | 0.80 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ADORA2A 1/4885ADORA3 7/4885ADORA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.